Dionex to purchase ESA Biosciences’ HPLC portfolio

Friday, 25 September, 2009

Dionex has entered into an asset purchase agreement with ESA Biosciences, a wholly owned subsidiary of Magellan Biosciences, to purchase ESA Biosciences’ HPLC-related products, HPLC clinical assays, laboratory services and assets.

This acquisition will add three HPLC detector families to the Dionex HPLC product portfolio:

  • Corona Family of Universal Charged Aerosol Detectors (CAD) is the ‘universal’ HPLC detector targeting pharmaceutical and biopharmaceutical development, manufacturing and QA/QC processes.
  • CoulArray and Coulochem detectors are electrochemical detectors targeting neuroscience, clinical, and metabolomics research applications.

Combined with Dionex expertise in electrochemistry detection for carbohydrates and glycobiology, this acquisition will position Dionex as the leading provider of comprehensive electrochemistry solutions for liquid chromatography.

Related News

QIMR Berghofer signs strategic partnership with Nakanoshima Qross

QIMR Berghofer and Japanese biomedical innovation hub Nakanoshima Qross have signed a strategic...

Dr Chris Baldwin is new HaemaLogiX CEO and Managing Director

Having commenced in January, Dr Chris Baldwin is clinical stage Australian biotechnology company...

Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO

To lead the commercialisation of Vaxxas's proprietary high‑density microarray patch (HD‑MAP)...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd